Topic

Aetna (CVS Health)

A collection of 1351 issues

Renewing Ruconest (C1 Esterase Inhibitor) Approval with Aetna CVS Health in Florida: Timeline, Documentation & Bridge Options

Answer Box: Ruconest Renewal Quick Start Aetna CVS Health requires annual renewal of Ruconest (C1 esterase inhibitor) approval in Florida, typically 30-60 days before your current authorization expires. Key requirements include updated HAE diagnosis confirmation, documented clinical response (reduced attack frequency/severity), and specialist oversight. Start renewal 60-90 days early

Myths vs. Facts: Getting Amondys 45 (casimersen) Covered by Aetna (CVS Health) in Michigan - Complete 2025 Guide

Quick Answer: Getting Amondys 45 (casimersen) Covered by Aetna (CVS Health) in Michigan Eligibility: Requires genetic testing confirming DMD with exon 45-skippable mutation, specialist prescription, and documented ambulatory function (≥300m on 6-minute walk test). Fastest path: Submit complete Aetna precertification form with genetic report, specialist notes, and functional assessments. First

How to Get Xenpozyme (olipudase alfa-rpcp) Covered by Aetna (CVS Health) in California: Appeals Guide & Templates

Answer Box: Getting Xenpozyme Covered by Aetna (CVS Health) in California Xenpozyme (olipudase alfa-rpcp) requires prior authorization from Aetna (CVS Health) in California. Your fastest path to approval: 1) Have your doctor submit a prior authorization request with ASMD diagnosis confirmation (enzyme assay and genetic testing), 2) Include documentation of

Get Vanflyta (Quizartinib) Covered by Aetna CVS Health in New Jersey: Complete Forms & Appeals Guide

Answer Box: Getting Vanflyta (Quizartinib) Covered by Aetna CVS Health in New Jersey Vanflyta (quizartinib) requires prior authorization from Aetna CVS Health for all New Jersey members. The fastest approval path involves: 1) Submit PA through CVS Caremark Provider Portal with FLT3-ITD test results and baseline EKG (24-48 hours), 2)

How to Get Firazyr (Icatibant) Covered by Aetna CVS Health in California: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Firazyr (Icatibant) Covered by Aetna CVS Health in California Firazyr (icatibant) is excluded from most Aetna CVS Health formularies in California, requiring a formulary exception and prior authorization for coverage. Your fastest path to approval: (1) Have an HAE specialist submit a formulary exception with documented HAE

Work With Your Doctor to Get Soliris (eculizumab) Approved by Aetna (CVS Health) in New Jersey

Quick Answer: Getting Soliris Approved by Aetna (CVS Health) in New Jersey Eligibility: Soliris (eculizumab) requires prior authorization from Aetna (CVS Health) for FDA-approved conditions including PNH, atypical HUS, generalized myasthenia gravis, and NMOSD. Fastest path: Submit complete prior authorization with diagnostic confirmation, vaccination proof, and detailed medical necessity letter

Getting Elzonris (Tagraxofusp-erzs) Covered by Aetna CVS Health in Florida: Prior Authorization, Appeals & Financial Assistance Guide

Answer Box: Getting Elzonris Covered by Aetna in Florida Elzonris (tagraxofusp-erzs) requires prior authorization from Aetna CVS Health for BPDCN treatment. The fastest path: 1) Confirm your plan's formulary status at aetna.com/formulary, 2) Submit PA request with BPDCN pathology report and treatment history via phone (1-855-240-0535)

Myths vs. Facts: Getting Poteligeo (mogamulizumab-kpkc) Covered by Aetna (CVS Health) in Ohio

Answer Box: Getting Poteligeo Covered by Aetna (CVS Health) in Ohio To get Poteligeo (mogamulizumab-kpkc) covered by Aetna (CVS Health) in Ohio, you need prior authorization with documented mycosis fungoides or Sézary syndrome diagnosis and evidence of at least one failed systemic therapy. Key steps: 1) Gather pathology report and

How to Get Darzalex (Daratumumab) Covered by Aetna CVS Health in California: Complete Prior Authorization Guide

Quick Answer: Getting Darzalex Covered by Aetna CVS Health in California Darzalex requires prior authorization from Aetna CVS Health. The fastest path: (1) Submit complete PA forms with documentation showing bortezomib failure/intolerance, (2) Include detailed medical necessity letter with ICD-10 codes and treatment history, (3) If denied, file internal

Oxbryta (Voxelotor) Denied by Aetna (CVS Health) in Georgia: Understanding the 2024 FDA Withdrawal and Your Appeal Options

Answer Box: Oxbryta (Voxelotor) Coverage Status Oxbryta (voxelotor) is no longer FDA-approved as of September 2024 due to safety concerns showing increased vaso-occlusive crises and deaths. Aetna (CVS Health) now denies all Oxbryta claims based on loss of FDA approval. Your next steps in Georgia: 1) Consult your hematologist immediately